SITC Meeting | Conference

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14th 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

November 14th 2020

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

PVSRIPO Shows Promising Antitumor Activity in Refractory Melanoma

November 14th 2020

November 14, 2020 – Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate of 33% among all patients with anti–PD-1 refractory melanoma.

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13th 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

Early Efficacy Data With RP2 in Advanced Solid Tumors

November 13th 2020

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

Dr. George on the Specificity of Cabozantinib in RCC

November 13th 2020

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

Urelumab Induces Additive Benefit With Vaccine/Nivolumab Combo in Pancreatic Cancer

November 13th 2020

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13th 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Bempegaldesleukin/Nivolumab Combo Upholds Durable Benefit in Metastatic Melanoma

November 13th 2020

November 13, 2020 - The combination of bempegaldesleukin and the PD-1 inhibitor nivolumab elicited a confirmed best overall response rate of 53% in efficacy-evaluable patients with metastatic melanoma.

Herpes Simplex-1 Oncolytic Showcases Antitumor Activity Across Heavily Pretreated Solid Tumors

November 13th 2020

November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors

x